{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000059","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.659680+00:00","generated_at":"2026-05-24T20:54:48.690078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track","bullets":["Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.","Cash, equivalents and restricted cash $214.3M at Dec 31, 2024; expected to fund operations into mid-2027.","Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; FDA SPA agreement secured.","Preliminary Phase 2 SLE data expected 2H25; Phase 2 pediatric basket trial to initiate 2H25 in select autoimmune indications.","Dosing ongoing in first-in-human Phase 1 trial of Descartes-15 for multiple myeloma."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000059","json":"https://secwatch.observer/filing/0001453687-25-000059.json","markdown":"https://secwatch.observer/filing/0001453687-25-000059.md","text":"https://secwatch.observer/filing/0001453687-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/0001453687-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/rnac-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T20:54:48.690078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}